The Product Monograph: Twelve Items from Specifications to Disposal

1. Key takeaways

The product monograph (Monografía del producto) is the longest single document in a Nicaraguan registration file. Item 12 of Chapter 6 of NTON 24001:2023 sets out twelve sub-items (a to l): technical specifications, clinical evaluation, biocompatibility, finished product analytical methodology, stability studies, sterilisation methodology, sterilisation or calibration validation, analytical method validation, disposal method, technical vigilance plan, labelling and packaging, and instructions or package insert. The clinical evaluation is mandatory for class III and class IV, while for class II it depends on the therapeutic or diagnostic claims.

• Twelve sub-items cover the whole technical file, from specifications to the disposal method and the vigilance plan.
• Clinical evaluation is tiered by risk class, so the classification decision directly determines the length of the monograph.
• Biocompatibility offers three alternative routes where the manufacturer has no data of its own.
• A product that declares no shelf life is not exempt but must file a manufacturer declaration instead.
• The labelling artwork must match the application form and the CLV word for word.

2. Legal basis

The table follows item 12 sub-item by sub-item, grouping the provisions as they appear in the standard so that the drafting of each section of the monograph can be checked against its source.

3. Expert insights

Insight 1: the clinical evaluation is tiered by class. NOTA 1 states aplica de manera obligatoria para los dispositivos médicos de nivel de riesgo III y IV, and NOTA 2 provides that for class II se tomará en consideración las indicaciones y reivindicaciones terapéuticas o diagnósticas previstas. Class I carries no such requirement. This mirrors the risk semantics of item 33 of the Chapter 4 definitions, where class III is medium-high and class IV the highest, so the classification decision directly determines the size of the monograph.

Insight 2: the clinical evaluation itself has seven internal elements, b.i to b.vii: product and manufacturer profile; product description and intended application; intended therapeutic or diagnostic indications and claims; evaluation context and choice of clinical data type; summary of clinical data; data analysis covering performance, safety and labelling; and the conclusion. A single overview will be returned. The seven elements should each appear as a separate section within the monograph.

Insight 3: biocompatibility offers three alternative routes. Sub-item c allows published clinical studies of the same or equivalent technology, comparability studies that demonstrate similarity of intended use, technical characteristics and biology, or the safety parameters laid down in international standards. For companies without data of their own, these routes are more workable than commissioning new testing at short notice.

Insight 4: the stability section is more demanding for self-testing and home-use devices and for reagent kits. Under sub-item e, where components are stored at different temperatures, separate stability studies are required for each, and the label artwork must clearly state the refrigeration or storage conditions. The provision ties the stability study to the label design.

Insight 5: a product that declares no shelf life is not exempt; it substitutes a manufacturer’s declaration. The NOTA to sub-item e reads En el caso de productos que no declaren vida útil, debe presentarse declaración del fabricante. This dovetails with block e.iv of item 2 of Chapter 6, which requires the shelf life to be entered on the application form.

Insight 6: the technical vigilance plan must name the person responsible for executing it in the country. Sub-item j requires indicando el responsable de ejecutar dicho programa en el país. The document brings a post-market obligation forward into the registration stage; it is the link between the registration file and post-market compliance, and the basis on which the vigilance system is subsequently built.

Insight 7: labelling may be filed as an original or as artwork, but it must match the application form and the CLV. Sub-item k requires the labelling to conform to the application form and the CLV (conforme el formato de solicitud y el Certificado de Libre Venta). Consistency across the application form, the CLV and the label artwork is one of the checks performed at preliminary review.

4. Practical recommendations

• Set the depth of the monograph by class: clinical evaluation is mandatory for class III and IV, claim-dependent for class II, and not required for class I.
• Write the clinical evaluation as separate sections following the seven elements b.i to b.vii, rather than condensing them into an overview.
• Assess the three biocompatibility alternatives first: published studies of the same technology, comparability studies, and international standard safety parameters.
• For multi-component products, perform stability studies component by component and state the storage conditions on the label artwork.
• For products with no declared shelf life, prepare the manufacturer’s declaration and align it with block e.iv of the application form.
• Name the domestic responsible person in the technical vigilance plan, and build the subsequent vigilance system on that appointment.
• Check the label artwork, the application form and the CLV word by word for consistency.

5. Verification checklist

• □ Whether the clinical evaluation is mandatory has been confirmed by risk class (mandatory for III and IV, claim-dependent for II)
• □ The clinical evaluation is written as separate sections following the seven elements b.i to b.vii
• □ The three biocompatibility alternatives have been assessed and one selected
• □ For multi-component products, stability studies are submitted per component and the storage conditions appear on the label artwork
• □ For products with no declared shelf life, a manufacturer’s declaration is prepared and matches block e.iv of the application form
• □ The technical vigilance plan names the person responsible for execution in the country
• □ The label artwork, application form and CLV have been reconciled word for word

Related reading: [Sample rules: the eighty percent shelf life and the exemptions](/nicaragua-medical-device-registration/commercial-sample-eighty-percent-shelf-life/) | [The fourteen registration items in full: Chapter 6 item by item](/nicaragua-medical-device-registration/fourteen-registration-requirements/) | [The five stages of registration: preliminary review, evaluation, issuance, first-import analysis and release](/nicaragua-medical-device-registration/five-stage-registration-process/)

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com